Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.

A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT) , triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit ...

The Asian Investor sees significant improvement in XPeng’s (XPEV) vehicle margin profile, leading to a more positive outlook on the stock. In contrast, Seeking Alpha analysts have made notable ...

Sarepta Therapeutics obtained traditional FDA approval for ambulatory DMD patients and accelerated approval for non-ambulatory DMD patients with a confirmed mutation in the DMD gene on the 20th of ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

What To Know: Under privately negotiated exchange agreements, Sarepta will swap about $700 million in aggregate principal amount of its existing convertible notes for approximately $602 million in new ...

Sarepta Therapeutics ( ($SRPT) ) has provided an announcement. On August 20, 2025, Sarepta Therapeutics entered into exchange agreements with ...

Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock declined 3.3% in pre-market trading Thursday after the company announced a refinancing of approximately $700 million of its 1.25% Convertible ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

(Bloomberg) — Sarepta Therapeutics Inc. (SRPT) landed a deal with investors to restructure around $700 million of debt, giving the company a reprieve as it recovers from a controversy over its gene ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer talked about. A caller asked for Cramer’s outlook on the stock, and he commented: “Oh God. I was hoping it’s not Sarepta. I don ...